June is Cataract Awareness Month - click here for FREE healthy vision tips
Glaucoma Support
damage to the optic nerve
Glaucoma is a group of eye conditions that damage the optic nerve, the health of which is vital for good vision. This damage is often caused by an abnormally high pressure in your eye. Glaucoma is one of the leading causes of blindness for people over the age of 60.
- Click here for: Glaucoma clinical research
Can-C Glaucoma Support*
"There is nothing, that we know of, more effective then topically delivered N-acetyl-carnosine Can-C™ to reverse oxidation in the ocular environment"
Dr. Mark Babizhayev MA PhD
1% N-acetylcarnosine Can-C eye drops™
How do Can-C eye drops help with Glaucoma?
- Unique anti-glycation properties effectively reverse oxidation (cross linking of proteins) that block the outflow-pathway of the eye, resulting in improved eye-pressure management.
- Protect against oxidative stress both in the lipid phase of cellular membranes and in the aqueous environment.
- Efficiently reverse free-radical induced oxidation in the entire ocular environment.
Healthy eyes contain high levels of the natural antioxidant L-Carnosine. Interestingly, the eyes of those suffering from degenerative ocular diseases such as Glaucoma were found to be highly deficient in L-Carnosine. Can-C™ Eye Drops contain N-acetyl-carnosine (NAC) that metabolizes into L-Carnosine in the eye, re-establishing youthful L-Carnosine levels to help counter oxidative stress and improve eye pressure management, providing targeted support for those who suffer from Glaucoma.
The prime ingredient in Can-C™ is a proprietary form of N-Acetyl-Carnosine (NAC), which acts as both a stabilizer and carrier for L-Carnosine, safely delivering it into the fluid area of the eye surrounding the lens, allowing Carnosine to access the areas it needs to in order to act as a natural and highly effective antioxidant that protects and heals the eye from Glaucoma and other ocular disease.
In clinical trials, Can-C™ eye drops applied daily were shown to reverse protein aggregation (oxidation) and inflammation in the majority of subjects thereby allowing the eyes’ natural repair mechanisms to address the causative factors of most ocular conditions such as eye pressure management and cataract.
Clinical Studies
N-alpha-Acetylcarnosine is proposed for treatment of ocular disorders that have a component of oxidative stress in their genesis (glaucoma, cataracts, retinal degeneration, ocular inflammation…)
“The advantage of N-alpha-acetylcarnosine and its bioactivated principle L-carnosine as universal antioxidants relates to their ability to give efficient protection against oxidative stress both in the lipid phase of biological membranes and in aqueous environments.”
Can-C + Nac-C Glaucoma Support*
"The finding of a protective effect of vitamin E and N-acetyl-cysteine (a key component of glutathione) adds to the growing evidence that antioxidants are beneficial in POAG"
Dr. Yuan He
+
1% N-acetylcarnosine Can-C eye drops™ + Nac-C Plus Capsules
Who it's for
For those looking to impede the progression of and ultimately reverse vision loss from glaucoma.
What do the Nac-C Plus capsules do?
- Increase the antioxidant activity of Can-C™ Eye Drops and length of time they remain active in the eye.
- Accelerate the healing response due to the synergy between Can-C eye drops and the systemic benefits of Nac-C Plus capsules.
- Enhanced free radical protection and reduction of oxidation through multiple pathways within the eye.
Molecular biologist Dr. Mark Babizhayevs’ groundbreaking research demonstrated that N-Acetylcarnosine (NAC) is effective when applied to the eyes via drops to reverse the oxidation buildup causing Glaucoma progression and eye pressure elevation.
Independent Study finds specific Amino Acids and Anti-Oxidants provide targeted support for those who suffer from IOP and Glaucoma. The independent study below notes that effectively reducing or even reversing oxidation may facilitate a healing response in the trabecular meshwork or outflow pathway in the eyes of glaucoma patients, a key suspect in the progression of POAG is local oxidative stress. Oxidative free radicals and reactive oxygen species (ROS) are reported to trigger degeneration in the trabecular meshwork, subsequently leading to increases in IOP and glaucoma.
The study provides evidence that mitochondrial dysfunction is a possible mechanism for the loss of trabecular meshwork cells in POAG. They also report that the antioxidants vitamin E and n-acetyl cysteine (NAC), can reduce the progression of Glaucoma. Reversing oxidation may be protective of and facilitate a healing response in the trabecular mesh-work or outflow pathway in the eyes of glaucoma patients.
Clinical Studies
Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants
There is growing evidence that oxidative stress contributes to the progression of primary open-angle glaucoma (POAG).
